enGene Holdings Inc.
ENGNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 18, 2026 | Morgan Stanley | Judah Frommer | $3.00(+72%) | $1.74 | StreetInsider |
| Jun 16, 2026 | H.C. Wainwright | Andres Maldonado | $4.00(+126%) | $1.77 | StreetInsider |
| May 14, 2026 | UBS | $2.00(+23%) | $1.63 | TheFly | |
| May 8, 2026 | Leerink Partners | Market Perform | $2.00(+16%) | $1.72 | TheFly |
| May 8, 2026 | Raymond James | $4.00(+133%) | $1.72 | TheFly | |
| May 8, 2026 | Piper Sandler | Allison Bratzel | $4.00(+133%) | $1.72 | TheFly |
| May 8, 2026 | Wells Fargo | $2.00(+16%) | $1.72 | TheFly | |
| Mar 9, 2026 | Raymond James | Sean McCutcheon | $27.00(+247%) | $7.79 | StreetInsider |
| Jan 30, 2026 | Jefferies | $28.00(+173%) | $10.27 | TheFly | |
| Dec 3, 2025 | H.C. Wainwright | Andres Maldonado | $25.00(+218%) | $7.86 | StreetInsider |
| Nov 12, 2025 | Oppenheimer | Leland Gershell | $33.00(+248%) | $9.47 | StreetInsider |
| Nov 12, 2025 | UBS | $10.00(+13%) | $8.82 | TheFly | |
| Nov 18, 2024 | JMP Securities | Silvan Tuerkcan | $18.00(+172%) | $6.61 | StreetInsider |
| Sep 27, 2024 | Leerink Partners | Mani Foroohar | $17.00(+181%) | $6.05 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citizens | maintain | Market Perform | Sep 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 8, 2026 |
| Morgan Stanley | downgrade | Equal Weight →Underweight | Jun 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 16, 2026 |
| UBS | maintain | Neutral | May 14, 2026 |
| Guggenheim | downgrade | Buy →Neutral | May 8, 2026 |
| Citizens | downgrade | Market Outperform →Market Perform | May 8, 2026 |
| Wells Fargo | downgrade | Overweight →Equal Weight | May 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2026 |
| Piper Sandler | downgrade | Overweight →Neutral | May 8, 2026 |
| Oppenheimer | maintain | Outperform | Mar 11, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 9, 2026 |
| Oppenheimer | maintain | Outperform | Nov 12, 2025 |
| Morgan Stanley | maintain | Overweight | Nov 12, 2025 |
| UBS | maintain | Neutral | Nov 12, 2025 |
| Citizens | maintain | Market Outperform | Nov 12, 2025 |
| Morgan Stanley | maintain | Overweight | Sep 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 8, 2025 |
| JMP Securities | maintain | Market Outperform | Apr 29, 2025 |
| Morgan Stanley | maintain | Overweight | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2025 |
| UBS | downgrade | Buy →Neutral | Feb 14, 2025 |
| JMP Securities | maintain | Market Outperform | Dec 23, 2024 |
| JMP Securities | maintain | Market Outperform | Dec 6, 2024 |
Earnings History
Next report: Dec 22, 2026 · EPS est. $-0.48| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 8, 2026 | $-0.47 | $-0.43 | — | — |
| Jun 15, 2026 | $-0.43 | $-0.48 | — | — |
| Mar 9, 2026 | $-0.44 | $-0.55 | — | — |
| Dec 22, 2025 | $-0.73 | $-0.57 | — | — |
| Sep 11, 2025 | $-0.57 | $-0.50 | — | — |
| Jun 12, 2025 | $-0.51 | $-0.50 | — | — |
| Mar 10, 2025 | $-0.48 | $-0.37 | — | — |
| Dec 19, 2024 | $-0.34 | $-0.40 | $480.0K | — |
News
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: UBS Global Biopharma Conference 2026 Date: Monday, November 16, 2026 Time: 3:20 p.m. GMT / 10:20 a.m. ET Format: Fireside Chat Jefferies Global Healthcare Conference in London Date: Thursday, November 19, 2026 Time: 10:30 a.m. GMT / 5:30 a.m. ET Format:.
enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned an average recommendation of "Hold" from the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, eight have given a hold rating, three have issued a buy rating and one has given
enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle invasive bladder cancer, or NMIBC.
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, no.
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month durability, but management is pursuing a surfactant cohort to address efficacy. Cost-saving measures, including a 50% workforce reduction, extend ENGN's cash runway into 2029, supporting operations through pivotal BLA milestones.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. “As we move through the second half of 2026, our focus is on maturing regulatory endpoints data from LEGEND's pivotal cohort and our planned engagement with the FDA regarding a BLA filing for detalimogene," said Ro.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026 Time: 10:15 a.m. ET Format: Fireside Chat Morgan Stanley 24th Annual Global Healthcare Conference Date: Monday, September 14, 2026 Time: 7:00 a.m. ET Format: Fireside Chat H.
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 64.2% of enGene shares are
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy.
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript